# OnCo record marengo-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/marengo-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "marengo-therapeutics" ;
  schema:name "Marengo Therapeutics"@en ;
  schema:description "Marengo Therapeutics, of Cambridge, Massachusetts, makes antibodies that bind part of the T-cell receptor to activate selected subsets of a patient's T cells. Its lead, invikafusp alfa, is in trials in tumours with a high mutational burden that have stopped responding to checkpoint drugs, and with an antibody-drug conjugate in breast cancer."@en ;
  schema:url <https://onco.cc/companies/marengo-therapeutics/>, <https://marengotx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://marengotx.com/>, <https://marengotx.com/pipeline/>, <https://marengotx.com/news-investors/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/nectin4/> ;
  onco:trials <https://onco.cc/trials/nct05592626/>, <https://onco.cc/trials/nct06827613/> .